ALUPENT
LOE ApproachingNDAORALTABLETPriority Review
Approved
May 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALUPENT is an oral small-molecule tablet approved in 1974 by Boehringer Ingelheim. The specific indication and mechanism of action are not documented in available data. This is a legacy product with a long commercial history.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), suggesting a consolidating team focused on managed decline and generic transition support.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and LOE approaching, this product offers limited career growth but valuable experience in mature portfolio management and regulatory complexity. Roles focus on maintaining compliance and supporting the transition to generic competition.
Regulatory Affairs SpecialistBrand Manager – Generic Transition
Worked on ALUPENT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.